Lipid metabolism in patients with hematologic cancers


Cite item

Abstract

It is considered that hypercholesterolemia is life-threatening and low cholesterol levels are a positive factor. However, taking into consideration the fact that cholesterol plays a key role in cell proliferation, it should be remembered that its low blood level may be linked to high cholesterol demands from neoplastic cells. The literature review analyzes the results of recent investigations of lipid metabolism in patients with hematologic cancers and their other types. All given investigations show a significant reduction in the serum levels of total cholesterol and high-density lipoproteins in patients with hematological disease at its onset. The data for other indicators of the lipid transport system are ambiguous. Such changes have been elucidated to be associated with the accumulation of cholesterol in the leukemia cells due to enhanced synthesis de novo, a more active absorption from circulation and blocked release of its surplus. If the disease runs a favorable course, lipid metabolic parameters become normalized and, in case of remission, correspond to those seen in healthy individuals. They continue to decline in patients with disease progression. This allows the consideration of cholesterol, its fractions, and apolipoproteins as biochemical prognostic markers in hematological cancer patients and as indicators for assessment of treatment results. In addition, there is evidence for the effect of chemotherapeutic agents on lipid metabolism. Recent attempts to elaborate new treatment strategies, by using the current knowledge on the role of lipid metabolism in cancers, are considered.

About the authors

S G Vladimirova

L N Tarasova

References

  1. Титов В.Н. Жирные кислоты, липиды (транспортные формы жирных кислот) и аполипопротеины (липидпереносящие макромолекулы) — единая функциональная система. Клиническая лабораторная диагностика. 2007;1:3-10.
  2. Безуглов В.В., Коновалов С.С. (ред.). Липиды и рак. Очерки липидологии онкологического процесса. СПб.: Прайм-ЕВРОЗНАК; 2009.
  3. Титов В.Н., Лисицын Д.М. Жирные кислоты. Физическая химия, биология и медицина. М.-Тверь: Триада; 2006.
  4. Губарева А.Е. Обмен липидов. В кн.: Северин Е.С. (ред) Биохимия: учебник. М.: ГЭОТАР-МЕД; 2003.
  5. Rao KN. The significance of the cholesterol biosynthetic pathway in cell growth and carcinogenesis (review). Anticancer Res. 1995;15(2):309-314.
  6. Sassano A, Katsoulidis E, Antico G et al. Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Res. 2007;67(9):4524-4532.
  7. Титов В.Н., Крылин В.В., Ширяева Ю.К. Профилактика атеросклероза. Позиционная специфичность триглицеридов, липазы крови, особые липиды молока, модификация жирных кислот растительных масел и животных жиров. Клиническая лабораторнаядиагностика. 2011;3:3-13.
  8. Houston MC, Fazio S, Chilton FH et al. Nonpharmacologic treatment of dyslipidemia. Prog Cardiovasc Dis. 2009;52(2):61-94.
  9. Титов В.Н. Атеросклероз как патология полиеновых жирных кислот. Биологические основы теории атерогенеза. М.: Фонд «Клиника XXI века»; 2002.
  10. Moschovi M, Trimis G, Apostolakou F et al. Serum lipid alterations in acute lymphoblastic leukemia of childhood. J Pediatr HematolOncol. 2004;26(5):289-293.
  11. Casalou C, Costa A, Carvalho T et al. Cholesterol Regulates VEGFR-1 (FLT-1) Expression and Signaling in Acute Leukemia Cells. Mol Cancer Res. 2011;9(2):215-224.
  12. Pillozzi S, Brizzi MF, Bernabei PA et al. VEGFR-1 (FLT-1), beta1 integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome. Blood. 2007;110(4):1238-1250.
  13. Qadir MI, Malik SA. Plasma lipid profile in gynecologic cancers. Eur J Gynaecol Oncol. 2008;29(2):158-161.
  14. Kuliszkiewicz-Janus M, Małecki R, Mohamed AS. Lipid changes occuring in the course of hematological cancers. Cell Mol Biol Lett. 2008;13(3):465-474.
  15. Cvetkovic Z, Cvetkovic B, Petrovic M еt al. Lipid profile as a prognostic factor in cancer patients. J BUON. 2009;14(3):501-506.
  16. Musolino C, Calabrò L, Bellomo G еt al. Lipid profile in hematologic neoplasms. Recenti Prog Med. 2002;93(5):298-301.
  17. Zalewska-Szewczyk B, Matusiak I, Wyka K еt al. Changes in the lipid profile in children with acute lymphoblastic leukaemia — the influence of the disease and its treatment. Med Wieku Rozwoj. 2008;12(4 Pt 2):1035-1040.
  18. Pugliese L, Bernardini I, Pacifico N еt al. Severe hypocholesterolaemia is often neglected in haematological malignancies. Eur J Cancer. 2010;46(9):1735-1743.
  19. Gonçalves RP, Rodrigues DG, Maranhão RC. Uptake of high density lipoprotein (HDL) cholesteryl esters by human acute leukemia cells. Leuk Res. 2005;29(8):955-959.
  20. Freeman MR, Solomon KR. Cholesterol and prostate cancer. J CellBiochem. 2004;91(1):54-69.
  21. Nygren C, von Holst H, Månsson JE, Fredman P. Increased levels of cholesterol esters in glioma tissue and surrounding areas of human brain. Br J Neurosurg. 1997;11(3):216-220.
  22. Vitols S, Norgren S, Juliusson G еt al. Multilevel regulation of low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in normal and leukemic cells. Blood. 1994;84(8):2689-2698.
  23. Tatidis L, Masquelier M, Vitols S. Elevated uptake of low density lipoprotein by drug resistant human leukemic cell lines. BiochemPharmacol. 2002;63(12):2169-2180.
  24. Steinherz PG. Transient, severe hyperlipidemia in patients with acute lymphoblastic leukemia treated with prednisone and asparaginase. Cancer. 1994;74(12):3234-3239.
  25. Nakagawa M, Kimura S, Fujimoto K еt al. A case report of an adult with severe hyperlipidemia during acute lymphocytic leukemia induction therapy successfully treated with plasmapheresis. TherApher Dial. 2008;12(6):509-513.
  26. Seah J, Lin K, Tai D еt al. Conservative management of L-asparaginase-induced hypertriglyceridemia in an adult patient: a case report and review of the literature. Onkologie. 2012;35(10): 596-598.
  27. Lashkari HP, Lancaster D, Atra A еt al. Symptomatic severe hypertriglyceridaemia with asparaginase therapy in acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma: is rechallenging safe? Int J Hematol. 2011;94(6):571-575.
  28. Nesheli HM, Tamaddoni A, Nesheli MM еt al. L-asparaginase induced hyperlipidaemia in acute lymphoblastic leukaemia. J PakMed Assoc. 2013;63(3):324-326.
  29. Cohen H, Bielorai B, Harats D еt al. Conservative treatment of L-asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010;54(5): 703-706.
  30. Annaloro C, Airaghi L, Saporiti G еt al. Metabolic syndrome in patients with hematological diseases. Expert Rev Hematol. 2012;5(4): 439-458.
  31. Joukhadar R, Chiu K. Severe hypercholesterolemia in patients with graft-vs-host disease affecting the liver after stem cell transplantation. Endocr Pract. 2012;18(1):90-97.
  32. Li HY, Appelbaum FR, Willman CL еt al. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood. 2003;101(9):3628-3634.
  33. Sassano A, Lo Iacono M, Antico G еt al. Regulation of leukemic cell differentiation and retinoid-induced gene expression by statins. Mol Cancer Ther. 2009;8(3):615-625.
  34. Sassano A, Altman JK, Gordon LI, Platanias LC. Statin-dependent activation of protein kinase Cδ in acute promyelocytic leukemia cells and induction of leukemic cell differentiation. Leuk Lymphoma. 2012;53(9):1779-1784.
  35. Banker DE, Mayer SJ, Li HY еt al. Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells. Blood. 2004;104(6):1816-1824.
  36. van der Weide K, de Jonge-Peeters S, Huls G еt al. Treatment with high-dose simvastatin inhibits geranylgeranylation in AML blast cells in a subset of AML patients. Exp Hematol. 2012;40(3): 177-186.
  37. Титов В.Н., Крылин В.В., Ширяева Ю.К. Профилактика атеросклероза. Избыток в пище пальмитиновой кислоты — причина гиперхолестеринемии, синдрома воспаления, резистентности миоцитов к инсулину и апоптоза. Клиническая лабораторнаядиагностика. 2011;2:4-15.
  38. Yao X., Tian Z. Dyslipidemia and colorectal cancer risk: a meta-analysis of prospective studies. Cancer Causes Control. 2015; 26(2):257-268.
  39. Allott EH, Howard LE, Cooperberg MR еt al. Serum lipid profile and risk of prostate cancer recurrence: Results from the SEARCH database. Cancer Epidemiol Biomarkers Prev. 2014;23(11): 2349-2356.
  40. Everatt R, Virvičiūtė D, Kuzmickienė I, Tamošiūnas A. Body mass index, cholesterol level and risk of lung cancer in Lithuanian men. Lung Cancer. 2014;85(3):361-365.
  41. Nelson E.R, Chang CY, McDonnell DP. Cholesterol and breast cancer pathophysiology. Trends Endocrinol Metab. 2014;25(12): 649-655.
  42. Rossi RE, Pericleous M, Mandair D еt al. The Role of Dietary Factors in Prevention and Progression of Breast Cancer. AnticancerRes. 2014;34(12):6861-6875.
  43. Berrino F, Villarini A, Traina A еt al. Metabolic syndrome and breast cancer prognosis. Breast Cancer Res Treat. 2014;147(1): 159-165.
  44. McDonnell DP, Chang CY, Nelson ER. The estrogen receptor as a mediator of the pathological actions of cholesterol in breast cancer. Climacteric. 2014;17(Suppl 2):60-65.
  45. McDonnell DP, Park S, Goulet MT еt al. Obesity, cholesterol metabolism, and breast cancer pathogenesis. Cancer Res. 2014;74(18):4976-4982.
  46. Nagel G, Stocks T, Späth D et al. Metabolic factors and blood cancers among 578,000 adults in the metabolic syndrome and cancer project (Me-Can). Ann Hematol. 2012;91(10):1519-1531.

Copyright (c) 2016 Vladimirova S.G., Tarasova L.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies